Elevance Health (NYSE:ELV) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Elevance Health (NYSE:ELV) had its price target hoisted by equities research analysts at Robert W. Baird from $331.00 to $393.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Robert W. Baird’s price target indicates a potential upside of 0.81% from the stock’s current price.

A number of other research analysts have also recently commented on the stock. Evercore restated a “hold” rating on shares of Elevance Health in a report on Tuesday, May 19th. Royal Bank Of Canada boosted their price objective on shares of Elevance Health from $358.00 to $439.00 and gave the company a “sector perform” rating in a research report on Thursday, July 9th. Barclays dropped their target price on shares of Elevance Health from $480.00 to $457.00 and set an “overweight” rating on the stock in a research note on Thursday. Morgan Stanley increased their price objective on Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a research note on Thursday, June 4th. Finally, Wall Street Zen lowered Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday. Fifteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $439.57.

Elevance Health Trading Down 8.7%

ELV opened at $389.85 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The stock’s 50 day moving average price is $399.67 and its 200-day moving average price is $355.07. Elevance Health has a one year low of $273.71 and a one year high of $436.24. The stock has a market cap of $84.66 billion, a price-to-earnings ratio of 16.58, a P/E/G ratio of 2.42 and a beta of 0.67.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $7.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.21 by $1.24. The company had revenue of $49.83 billion during the quarter, compared to analysts’ expectations of $48.88 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.Elevance Health’s revenue was up .8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $8.84 EPS. On average, equities analysts forecast that Elevance Health will post 26.86 EPS for the current year.

Insider Activity at Elevance Health

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the sale, the director directly owned 10,734 shares in the company, valued at $4,312,599.18. This represents a 1.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Elevance Health

A number of large investors have recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Elevance Health during the fourth quarter valued at about $1,058,165,000. Wellington Management Group LLP grew its position in shares of Elevance Health by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 8,289,976 shares of the company’s stock worth $2,906,051,000 after buying an additional 1,668,679 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Elevance Health by 27.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,446,185 shares of the company’s stock worth $2,610,261,000 after acquiring an additional 1,607,274 shares in the last quarter. Amundi lifted its position in Elevance Health by 145.7% during the first quarter. Amundi now owns 2,693,664 shares of the company’s stock valued at $788,570,000 after acquiring an additional 1,597,497 shares during the last quarter. Finally, Invesco Ltd. lifted its position in Elevance Health by 50.3% during the fourth quarter. Invesco Ltd. now owns 3,903,878 shares of the company’s stock valued at $1,368,505,000 after acquiring an additional 1,306,390 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Elevance Health beat Q2 expectations on both earnings and revenue, with EPS of $7.45 versus estimates around $6.18-$6.21 and revenue of $49.83 billion topping forecasts. Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: The company raised its 2026 adjusted EPS guidance to at least $27.00, signaling management is more confident in profit trends and medical cost control for the rest of the year. Elevance raises annual profit forecast on better medical cost management
• Positive Sentiment: Analyst sentiment remained supportive, with Truist lifting its price target to $475 and reiterating a buy rating after the earnings update. Elevance Health (NYSE:ELV) Price Target Raised to $475.00 at Truist Financial
• Neutral Sentiment: Recent earnings-call coverage highlighted growth opportunities in CarelonRx and operating improvements, but also noted that the company is navigating strain from higher costs and softer membership trends. Elevance Health earnings call: growth levers amid strain
• Negative Sentiment: Despite the earnings beat, some reports said the shares slipped on margin pressure and the company is leaving more Medicaid markets, which could weigh on investor sentiment around future growth. Elevance Health (ELV) Beats Q2 And Raises Outlook While Leaving More Medicaid Markets

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.